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Summary
We have previously shown that radiation increases HIF-1 activity in tumors, causing significant radioprotection of the
tumor vasculature. The impact that HIF-1 activation has on overall tumor radiosensitivity, however, is unknown. We reveal
here that HIF-1 plays an important role in determining tumor radioresponsiveness through regulating four distinct pro-
cesses. By promoting ATP metabolism, proliferation, and p53 activation, HIF-1 has a radiosensitizing effect on tumors.
Through stimulating endothelial cell survival, HIF-1 promotes tumor radioresistance. As a result, the net effect of HIF-1
blockade on tumor radioresponsiveness is highly dependent on treatment sequencing, with “radiation first” strategies
being significantly more effective than the alternative. These data provide a strong rationale for pursuing sequence-spe-
cific combinations of HIF-1 blockade and conventional therapeutics.S I G N I F I C A N C E
Radiation is used in treating approximately 500,000 cancer patients in the United States annually. Consequently, many people could
benefit from the development of new ways to make tumors respond better to radiation. We recently found that a crucial regulator
of gene expression in tumors, HIF-1, is activated by radiation. We undertook the current study to determine how HIF-1 activation
influences tumor radiosensitivity. Our results suggest that HIF-1 blockade may be a very effective means of overcoming tumor
radioresistance. However, because HIF-1 influences radiosensitivity in many complex ways, the success of this strategy requires
specific timing of its blockade relative to when radiotherapy is administered. This work may help optimize the use of HIF-1 inhibitors
with conventional tumor therapies.Introduction
Radiation plays an important role in the treatment of cancer.
Although modern technology has made it an effective tool,
dose-limiting normal tissue toxicities and radioresistant tumors
still lead to life-threatening radiation treatment failures. In order
to improve its therapeutic ratio, there has been much interest
in augmenting the effect of radiation on tumors by combining
it with molecularly targeted tumor therapeutics (Camphausen
and Tofilon, 2004). As this approach is beginning to show
promise, there is a continued need for the discovery of novel
critical molecular targets whose inhibition might enhance ra-
diotherapeutic response.
Hypoxia-inducible factor-1 (HIF-1) is an excellent potential
candidate for targeted inhibition to improve radiation outcome.
It is a nuclear transcription factor whose activity is promoted
by hypoxia (Wang and Semenza, 1993), oxidative stress (Chan-
del et al., 1998), and oncogenes (Laughner et al., 2001; Zundel
et al., 2000); as such, it is commonly upregulated in tumors
(Zhong et al., 1999). It influences tumor biology by regulating
60+ genes that contribute to crucial behaviors such as angio-
genesis (Maxwell et al., 1997), cell death (Sowter et al., 2001),
and metabolism (Firth et al., 1995; Semenza et al., 1994). The
importance of HIF-1 is underscored by its association with
poor disease-specific outcomes for multiple cancer types (BosCANCER CELL : AUGUST 2005 · VOL. 8 · COPYRIGHT © 2005 ELSEVIER INet al., 2003; Shibaji et al., 2003). It also plays a very important
role in modulating treatment responsiveness. High tumor HIF-1
activity is an independent predictor of poor prognosis after ra-
diotherapy (Aebersold et al., 2001; Koukourakis et al., 2002).
For this reason, the interplay between radiotherapy and HIF-1
warrants detailed investigation.
We recently found that ionizing radiation significantly upregu-
lates HIF-1 activity in tumors (Moeller et al., 2004). Radiation
causes tumor oxygenation to increase, causing, in turn, both
the accumulation of tumor-reactive oxygen/nitrogen species
and the depolymerization of stress granules. These two events
lead to increased expression of HIF-1 and its target downstream
genes. As a result, the increased expression of HIF-1-regulated
cytokines delivers survival signals to tumor endothelium, re-
sulting in tumor radioresistance through vascular radiopro-
tection.
This prior work strongly supports the claim that HIF-1 is a
rational target for tumor radiosensitization. However, the com-
plex roles of this protein require that caution be taken before
moving this strategy forward. Many of the phenotypes regu-
lated by HIF-1 activity are known modifiers of cellular radiosen-
sitivity, including apoptotic potential (Rupnow and Knox, 1999),
mitotic potential (Denekamp, 1986), and metabolic rate (Rojas
and Denekamp, 1989). These pleiotropic effects make it diffi-C. DOI 10.1016/j.ccr.2005.06.016 99
A R T I C L Ecult to predict whether a HIF-1-inhibiting strategy would have
an overall positive or negative impact on tumor radiosensitivity.
Therefore, we investigate here (1) how HIF-1 blockade influ-
ences tumor apoptosis, metabolism, proliferation, and angio-
genesis, and (2) how each of these factors, in turn, affects ra-
diosensitivity. The results of these studies are then used to
rationally design and test strategies for the optimal timing of
HIF-1 blockade relative to radiotherapy. This work may be vital
to the clinical development of HIF-1 inhibitors for use with
other treatment modalities.
Results
Establishing models of HIF-1 inhibition
We first sought to establish high-specificity molecular models
of HIF-1 inhibition using RNA interference and directed protein
mutagenesis. Retroviral vectors were designed to generate
constitutive expression of HIF-1α-targeting or scrambled siRNA
in transduced 4T1 cells (Figure 1A). Also, a dominant-negative
mutant was created from HIF-1α cDNA using site-directed mu-
tagenesis (Figure 1B). “Stitching” PCR reactions were run on
HIF-1α cDNA to mutate the 25th and 30th residues, which had
been previously identified as critical for DNA binding and
downstream gene transcription (Michel et al., 2002). Further,
the primers were designed to amplify the amino-terminal half
of the protein only, eliminating from the product the oxygen-
dependent degradation motifs of the carboxy-terminal half of
the protein. This resulted in a HIF-1α mutant with oxygen-inde-
pendent stability and an inability to upregulate downstreamFigure 1. HIF-1 blockade model
A: Retroviral vectors were generated encoding
HIF-1α-targeting or scrambled siRNA and trans-
duced into 4T1 cells.
B: A dominant-negative HIF-1α mutant was cre-
ated via site-directed PCR mutagenesis. Four
primers (arrows) were used to amplify the N-ter-
minal half of murine HIF-1α cDNA while mutat-
ing two residues in the DNA binding domain
(A25S, R30A). This product was cloned into a ret-
roviral vector and transduced into HCT116 and
PC-3 cells.
C: 4T1 cells transduced with HIF-1α-targeting
siRNA-expressing vectors demonstrated >90%
HIF-1α protein knockdown by immunoblot.
D: HCT116 cells transduced with the tet-induc-
ible dominant-negative HIF-1α (TRDNH) demon-
strated complete repression of the hypoxia-
stimulated increase in HRE-GFP fluorescence
intensity upon exposure to doxycycline, with
nonsignificant “leakiness” in the absence of
doxycycline (*p < 0.05 versus 21% O2). PC-3 cells
demonstrated similar results (data not shown).
Error bars represent the standard deviation of
the mean.100gene expression. The PCR product was cloned into a retroviral
vector designed to generate tetracycline-inducible expression
of the dominant-negative mutant in transduced HCT116 and
PC-3 cells.
These models were both very effective at inhibiting HIF-1.
The level of HIF-1α knockdown achieved by siRNA in 4T1 cells
was greater than 90% (Figure 1C). In HCT116 and PC-3 cells,
the tetracycline-responsive dominant-negative HIF-1α con-
struct was negligibly active in the absence of doxycycline, yet
was a strong HIF-1 inhibitor in its presence (Figure 1D). Inter-
estingly, 4T1 cells responded less well to the dominant-nega-
tive construct as compared to the anti-HIF-1α siRNA, and the
converse was true for HCT116 and PC-3 cells (data not
shown). Therefore, we used siRNA exclusively for 4T1 cells,
and our HIF-1α mutant exclusively for HCT116 and PC-3 cells
in the experiments to follow.
HIF-1 potentiates radiation-induced apoptosis
One way HIF-1 might impact tumor radiosensitivity is through
modulating apoptosis. HIF-1 has been shown to affect apopto-
sis in several ways. It stimulates upregulation of the proapo-
ptotic BNIP3 (Guo et al., 2001) and can directly stabilize p53
(An et al., 1998). There are also data to suggest that HIF-1
can exert an antiapoptotic influence under certain conditions
(Akakura et al., 2001). It is likely that the overall impact of HIF-1
on apoptosis is context dependent.
With these factors in mind, we first used the p53+/+ HCT116
line to examine how HIF-1 affects radiation-induced apoptosis.
HCT116 cells were irradiated with or without first being ex-CANCER CELL : AUGUST 2005
A R T I C L Eposed to a 24 hr period of hypoxia to activate HIF-1. Since
hypoxia lowers the relative efficacy of radiation (Berry et al.,
1970), hypoxic cells were reoxygenated 10 min prior to irradia-
tion for this experiment as well as those to follow. This way,
our results vary strictly as a function of differential hypoxia-
induced gene and protein regulation, not as a function of the
oxygen enhancement effect on radiation damage.
Caspase 3/7 activation and DNA fragmentation were used
to analyze the effects of radiation on early (6 hr) and late (48
hr) apoptosis, respectively. There was a significant difference
in the early apoptotic response to radiation between cells that
had been cultured in normoxia and hypoxia before irradiation
(hereafter referred to as “normoxic/irradiated” and “hypoxic/
irradiated,” respectively). Whereas normoxic/irradiated cells
underwent only modest caspase activation at 6 hr, this re-
sponse was markedly enhanced in the hypoxic/irradiated
group (Figure 2A). This potentiation was completely absent in
cells expressing the dominant-negative mutant, proving this to
be a HIF-1-dependent effect. DNA content analysis of these
cells 48 hr after irradiation demonstrated that a large fraction
of the hypoxic/irradiated group proceeded from caspase acti-
vation to apoptosis (24.2% ± 0.5%), and that this fraction was
markedly lower (3.6% ± 0.1%) in HIF-1-inhibited cells (Figure
2B). The decrease in the fraction of apoptotic cells in the HIF-1-
inhibited group was balanced by an increase in the G2/M pop-
ulation (59.3% ± 1.4% +dox versus 39.3% ± 0.1% −dox), sug-
gesting that the loss of HIF-1 shifts hypoxic/irradiated cells
from apoptotic to G2-arrested fates.
The impact of HIF-1 inhibition on apoptosis was also exam-
ined for tumor cells grown in vivo (Figure 2C). TUNEL-positiveFigure 2. HIF-1 is required for hypoxic potentia-
tion of radiation damage
A: Luminescent caspase 3/7 assay run on
HCT116 cells 6 hr after treatment with 0 or 8 Gy
of radiation. Cells were cultured for 24 hr under
normoxia (21% O2) or hypoxia (0.5% O2) prior to
irradiation. As with all experiments, hypoxic cells
were reoxygenated for 10 min immediately be-
fore irradiation. Caspase activity was signifi-
cantly enhanced after radiation for hypoxia-
stimulated cells, through a HIF-1-dependent
mechanism (*p < 0.05 versus −dox).
B: FACS analysis of DNA content in HCT116 cells
48 hr after receiving 8 Gy of radiation. Before
irradiation, cells were stimulated by 24 hr of hyp-
oxia and 10 min of reoxygenation. HIF-1 inhibi-
tion caused these cells to shift from apoptosis to
G2/M arrest (*p < 0.05 versus −dox). S phase
cells (data not shown) made up a very small
percentage of the total population for both
groups.
C: HCT116 tumors, with or without HIF-1 inhibi-
tion, were removed 48 hr after (sham) irradiation
(3 × 4 Gy). Sections were labeled by TUNEL stain-
ing, and the results were quantified by counting
the number of positive nuclei per high-powered
field. HIF-1 inhibition significantly suppressed
apoptosis (*p < 0.05 versus −dox). n = 5/group.
D: HCT116 cells were cultured for 24 hr under
normoxia or hypoxia and in the presence or ab-
sence of doxycycline, reoxygenated briefly prior to irradiation, and assayed for clonogenicity 7 days after irradiation. Exposure to hypoxia before irradiation
caused a significant left-shift in the survival curve (closed triangles; p < 0.05 versus 21% O2 and −dox), and HIF-1 inhibition abrogated this response
(open triangles).
Errors bars represent the standard deviation of the mean.CANCER CELL : AUGUST 2005nuclei were significantly less common in HIF-1-inhibited HCT116
tumors, both at baseline and 48 hr after irradiation.
Although these data indicate that HIF-1 inhibition protects
hypoxic cells from radiation-induced apoptosis, this may not
correlate with an effect on clonogenicity (Abend, 2003). From
a therapeutic standpoint, if the excess G2-arrested population
shown in Figure 2B does not eventually recover and demon-
strate clonogenic capacity, the effect of HIF-1 blockade may
be negligible. For this reason, clonogenic survival was deter-
mined for the HCT116 cells after radiation, with or without pre-
incubation under hypoxia, and with or without stimulation by
doxycycline (Figure 2D). Expressing the dominant-negative
mutant had no impact on clonogenicity of aerobic cells follow-
ing irradiation. In cells exposed to hypoxia before irradiation,
on the other hand, clonogenic survival was significantly en-
hanced by HIF-1 blockade, with a 2-log-kill isoeffect dose-
modifying factor (2L-DMF) of 1.22.
p53 is required for HIF-1-dependent apoptotic induction
Since it has been implicated previously in the link between
HIF-1 and apoptosis, we next sought to determine whether
p53 was required for the effects described above. HCT116
cells were cultured for 24 hr under normoxia or hypoxia, in the
presence or absence of doxycycline stimulation, and briefly
reoxygenated before irradiation. One hour after irradiation,
nuclear extracts were prepared from these groups and run on
a Western blot (Figure 3A). Radiation and hypoxia both led to
increased p53 immunoreactivity in nuclear extracts, but com-
bining the two stimuli did not further enhance this effect. Radi-101
A R T I C L EFigure 3. p53 is required for hypoxic potentiation
of radiation damage
A: Immunoblots of nuclear extracts prepared
from HCT116 cells 1 hr after radiation. Cells were
exposed to normoxia (21% O2) or hypoxia (0.5%
O2) for 24 hr, in the presence or absence of
doxycycline, before irradiation (8 Gy).
B: Immunoblots of whole-cell extracts from PC-3
cells transduced with a p53 expression vector
(p53) or control vector (VC).
C: Caspase 3/7 assay run on p53-transduced
PC-3 cells treated as in Figure 2A. Caspase ac-
tivity was significantly enhanced in cells irradi-
ated after hypoxic conditioning, in a HIF-1-
dependent fashion (*p < 0.05 versus −dox). Error
bars represent the standard deviation of the
mean.
D: Clonogenicity of p53-transduced PC-3 cells
treated as in Figure 2D prior to irradiation (10
Gy). Pretreatment with hypoxia significantly ra-
diosensitized these cells (p < 0.05 versus 21% O2
and −dox), through a HIF-1-dependent mecha-
nism. Error bars represent the standard deviation
of the mean.ation and hypoxia also both led to increased phospho-p53
(serine 15) immunoreactivity, and combining the two stimuli
lead to further p53 phosphorylation. Importantly, hypoxia/radi-
ation-induced p53 phosphorylation was abrogated by HIF-1 in-
hibition. These data provide strong evidence, then, that HIF-1
is required for enhancement of radiation-induced p53 activa-
tion by hypoxia. They also suggest that p53 may be required
for HIF-1-mediated potentiation of radiation-induced apoptosis
by hypoxia.
To further investigate this latter hypothesis, we engineered a
paired cell line in the PC-3 background distinguished only by
p53 expression status. This was accomplished by transducing
wild-type human p53 cDNA (a generous gift from V. Seewaldt)
into the p53 null PC-3 cell line (Figure 3B). Taking advantage
of the inducible HIF-1α mutant already established in this line,
we were then able to study the effects of hypoxia on radiation-
induced apoptosis in the presence or absence of both HIF-1
and p53 functionality. In native (p53 null) PC-3 cells, exposure
to hypoxia before radiation fails to augment subsequent cas-
pase 3/7 activation, DNA fragmentation, or loss of clonogenic
survival; accordingly, HIF-1 inhibition has no impact on these
outcomes (see Figure S1 in the Supplemental Data available
with this article online). For p53-expressing PC-3 cells, how-
ever, the response is quite different. As would be predicted,
caspase 3/7 activity was increased across the board after p53102reconstitution. However, caspase activity following hypoxia/
irradiation was dramatically higher for the p53-expressing cells
than it was for p53 null PC-3 cells. Moreover, the caspase ac-
tivity enhancement for this group was abrogated when HIF-1
was inhibited, as had been the case for the HCT116 cell line
(Figure 3C). DNA content analysis after 48 hr showed that the
p53-reconstituted PC-3 cells had a significant increase in the
apoptotic population after hypoxia/irradiation (15.2% ± 0.4%),
which was effectively blocked by HIF-1 inhibition (0.8% ±
0.4%). As was the case with the HCT116 line, the apoptotic
cell population was shifted to G2 arrest in HIF-1-inhibited cells
(data not shown). Finally, the impact of HIF-1 activity on the
clonogenicity of hypoxic/irradiated cells was shown again here
with p53-reconstituted PC-3 cells (Figure 3D). Once more, the
clonogenicity of normoxic cells was not affected by HIF-1
blockade. The radiosensitivity of hypoxic, HIF-1-inhibited cells
was similar to that of the normoxic cells. Hypoxic cells with
intact HIF-1 function, on the other hand, were significantly less
clonogenic following 10 Gy of radiation.
To summarize, HIF-1 promotes p53 phosphorylation at ser-
ine 15 in response to hypoxia and, more so, upon irradiation
after hypoxic conditioning. As a consequence, HIF-1 and p53
are both required for hypoxic potentiation of radiation-induced
caspase activation, apoptosis, and loss of clonogenicity.CANCER CELL : AUGUST 2005
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Recent work has provided strong evidence for the role of HIF-1
in regulating glucose metabolism and energy maintenance in
tumors (Griffiths et al., 2002). Glucose levels and metabolic ac-
tivity have been directly associated with tumor cell radiosensi-
tivity (Heller and Raaphorst, 1994; Luk and Sutherland, 1987).
Therefore, we sought to determine how HIF-1 inhibition would
alter energy metabolism in tumors, and how this effect might
influence overall radiosensitivity.
We first examined how HIF-1 inhibition influences glucose
consumption in our models. 4T1 and HCT116 cells were ex-
posed to 24 hr of normoxia or hypoxia, with or without HIF-1
inhibition, and were subsequently assayed for glucose con-
sumption rates (Figure 4A). There was an enhancement of glu-
cose consumption after exposure to hypoxia, and this effect
was abrogated by HIF-1 blockade for both cell lines. We hy-
pothesized that this impaired glucose utilization would lead to
decreased ATP production in HIF-1-inhibited cells. To test this
hypothesis, 4T1 and HCT116 cells were stressed by hypoxia
for 24 hr, with or without glucose deprivation, with or without
HIF-1 inhibition, and then assayed for total cellular ATP levels
(Figure 4B). Neither hypoxia nor glucose deprivation alone was
sufficient to deplete cellular ATP, whether the cells were HIF-1
inhibited or not (data not shown). When the two stressors were
combined, however, ATP levels fell for both groups. Consistent
with their impaired ability to consume glucose, the HIF-1-inhib-
ited cells experienced a significantly greater reduction in ATP
stores after the combined stress.
Next, 4T1 and HCT116 tumors were grown in mice to deter-
mine whether HIF-1 inhibition would influence ATP levels in
vivo (Figure 4C). Bioluminescence imaging was used to quan-
tify ATP concentrations in frozen tissue sections (Schwickert et
al., 1996). HIF-1 blockade caused a 5-fold reduction in overall
ATP levels for 4T1 tumors, and a 2-fold reduction for HCT116
tumors. Spatially, the loss of ATP was most significant near the
center of HIF-1-inhibited tumors, with levels at the periphery
being similar to that found in wild-type tumors. Similarly, HIF-1
blockade was also found to increase the area of central necro-
sis for both tumor types studied. The diameter of the viable rim
of tumor identified by H&E staining was significantly smaller in
HIF-1-inhibited tumors (4T1, 0.92 ± 0.48 mm; HCT116, 1.32 ±
0.63 mm) as compared to their controls (4T1, 4.94 ± 1.04 mm;
HCT116, 3.29 ± 0.61 mm; p < 0.05; n = 5/group).
The above data indicate that HIF-1 inhibition impairs tumor
energy metabolism, leading to a reduction in ATP levels and
cellular viability. As reduced metabolic rates have been linked
with radioresistance, we next examined whether inhibiting HIF-1
in nutrient-depleted cells would influence clonogenic survival
after irradiation. Wild-type PC-3 cells were chosen for this ex-
periment because hypoxia does not affect their clonogenicity
after irradiation (Figure S1); therefore, oxygenation could be
eliminated as a variable in the following experiment. PC-3 cells
were cultured for 24 hr under hypoxia, in high or low glucose
concentrations, with or without stimulation by doxycycline (Fig-
ure 4D). As before, the cells were briefly reoxygenated prior to
irradiation. HIF-1 blockade failed to affect clonogenic survival
in cells exposed to high glucose concentrations prior to irradia-
tion. For cells cultured in low-glucose conditions, however, sur-
vival curves were significantly right shifted. Low glucose alone
induced modest radioresistance in the PC-3 cells (2L-DMF =
1.14). Combining low glucose with HIF-1 blockade resulted inCANCER CELL : AUGUST 2005cells becoming significantly more radioresistant (2L-DMF =
1.49), consistent with the lowered energy state of these cells.
We also compared survival curves for HCT116 cells exposed to
hypoxia and doxycycline, with or without glucose deprivation
(Figure S2). Low glucose concentrations induced radioresis-
tance in these cells to a degree similar to that seen for PC-3
cells (2L-DMF = 1.31).
In summary, HIF-1 maintains glucose metabolism and ATP
production in tumor cells, most prominently in the center of
tumors, sustaining bioenergetics at a level required for high
cellular sensitivity to radiation.
HIF-1 proliferation effects vary with microenvironment
It has been reported that HIF-1 is required for cell cycle arrest
in response to hypoxia (Goda et al., 2003). Since cell cycle
phase also influences radiosensitivity, we next sought to inves-
tigate whether HIF-1 inhibition might impact tumor radiore-
sponsiveness through its effects on proliferation rate.
4T1 and PC-3 cells were cultured for 24 hr in hypoxic or
normoxic conditions, with high or low glucose concentrations
in the media. MTT assays showed that HIF-1-inhibited cells
were more viable than controls after hypoxia alone, but less so
after combined hypoxia and glucose deprivation (Figure 5A).
Analysis of DNA content revealed that cell cycle arrest was at
least in part responsible for these effects (Figure 5B). HIF-1
inhibition attenuated G1 blockade following hypoxia alone,
consistent with its role in promoting hypoxic growth arrest. In
contrast, the loss of HIF-1 promoted G1 arrest in response to
combined oxygen and glucose deprivation.
To determine whether these results are relevant to the micro-
environment encountered by tumors in vivo, patterns of cellu-
lar proliferation were analyzed in tumor sections using Ki-67
immunohistochemistry. There appeared to be qualitative differ-
ences between the groups in how proliferation indices varied
with the distance from perfused vasculature (Figure 5C). Quan-
titative analysis of these data revealed that there was, indeed,
distinct variation in the spatial patterns of proliferation between
the wild-type and HIF-1-inhibited groups (Figure 5D). For both
groups, proliferation indices fell off significantly as distance
from the vasculature increased (p < 0.05), as expected. There
was no significant effect of HIF-1 inhibition on the global prolif-
eration indices for the groups (p > 0.05). However, there was a
highly significant interaction between group and distance (p <
0.001). HIF-1 knockdown tumors were more proliferative in tis-
sues near vasculature (%240 m), whereas wild-type tumors
were more proliferative in tissues far from vasculature (R240
m). To control for potential differences in nuclear density be-
tween the groups, a similar analysis was run on sections coun-
terstained for total nuclei. In general, nuclear densities de-
creased with distance from perfused vasculature for both
groups, but there was no significant difference in nuclear den-
sity between the groups at any given distance (p > 0.05; data
not shown).
We next examined whether HIF-1 influences radiosensitivity
through regulating cellular proliferation rates. Wild-type PC-3
cells were again used here, as hypoxia does not affect their
clonogenicity after radiation, eliminating oxygenation as an ex-
perimental variable. PC-3 cells were cultured under hypoxic
conditions for 24 hr, with or without doxycycline stimulation,
and with or without aphidicolin-induced cell cycle synchroniza-
tion (Figure 5E). Next, the cells were briefly reoxygenated and103
A R T I C L EFigure 4. HIF-1 maintains tumor bioenergetics
A: Glucose consumption rates rise in 4T1 and
HCT116 cells exposed to hypoxia (0.5% O2) for
24 hr, and HIF-1 blockade completely inhibits this
response (*p < 0.05 versus control). Error bars
represent the standard deviation of the mean.
B: Whole-cell ATP levels in 4T1 and HCT116 ex-
posed to a combination of low oxygen (0.5%
O2) and either high glucose (HG; 5 g/l) or low
glucose (LG; 0.1 g/l) concentrations for 24 hr,
with or without HIF-1 inhibition. ATP levels fall for
each line in low-glucose conditions, but the ef-
fect is significantly more pronounced when HIF-1
is inhibited (*p < 0.05 versus control). Error bars
represent the standard deviation of the mean.
C: Ex vivo ATP bioluminescence. ATP is signifi-
cantly depleted in 4T1 and HCT116 tumors in re-
sponse to HIF-1 blockade (p < 0.05). Represen-
tative images are shown, along with mean ATP
concentrations (mM) displayed for each group,
with standard deviations in parentheses. Scale
bar, 500 m. n = 5/group.
D: PC-3 cells were cultured for 24 hr under hyp-
oxia, with high glucose (HG; 5 g/l)- or low glu-
cose (LG; 0.1 g/l)-containing media, with or
without doxycycline stimulation, and briefly re-
oxygenated prior to irradiation. Low glucose
concentrations caused a significant right-shift in
the survival curve (closed triangles; p < 0.05 ver-
sus HG and −dox), and HIF-1 inhibition further
enhanced this effect (open triangles; p < 0.05
versus LG and −dox). Error bars represent the
standard deviation of the mean.then immediately irradiated. Aphidicolin, which causes G1/S
cell cycle arrest, resulted in a slight right-shift in the survival
curve for hypoxic cells (2L-DMF = 1.14), likely through arresting
those cells which had escaped HIF-1-mediated cell cycle
blockade. It caused a significantly greater shift toward radiore-
sistance when applied to HIF-1-inhibited, hypoxic cells (2L-
DMF = 1.31), wherein a larger fraction of cells had escaped G1
blockade secondary to HIF-1 dysfunction. Similar results were
seen for HCT116 cells (Figure S3). These data suggest that
HIF-1 normally acts to lower radiosensitivity in hypoxic cells by
promoting cell cycle arrest. However, it also normally functions
to sustain mitotic rates for cells starved of both glucose and
oxygen, likely leading to relative radiosensitization of these
cells. Therefore, the overall impact of HIF-1 activity on tumor
radiosensitivity, due to its effects on proliferation, is likely de-
pendent on the microenvironment.104HIF-1 promotes vessel radioresistance
HIF-1-inhibiting compounds, delivered after radiation, lead to
significant destruction of tumor vasculature and prolonged
time to tumor regrowth after therapy (Moeller et al., 2004). Were
the sequence or timing of therapeutic delivery altered, how-
ever, it is unknown whether this approach would remain effec-
tive. It is possible, for example, that preradiation HIF-1 block-
ade might have antiangiogenic effects on tumors (Stoeltzing et
al., 2004). This could, conceivably, compromise radiotherapy
by decreasing tumor oxygenation—an effect previously described
for another antiangiogenic therapy (Murata et al., 1997). There-
fore, we next sought to investigate how HIF-1 blockade influ-
enced tumor vascularity in our models, and whether the timing
of HIF-1 inhibition would affect its overall impact on tumor ves-
sel radiosensitivity.
To begin, we first examined how HIF-1 blockade affects earlyCANCER CELL : AUGUST 2005
A R T I C L EFigure 5. HIF-1 maintains proliferative capacity
A: Viability of 4T1 and PC-3 cells exposed to 24 hr of hypoxia (0.5% O2) and high or low glucose (5 or 0.1 g/l) concentrations, as determined by MTT assay.
HIF-1-inhibited cells fare significantly better under hypoxia alone, but significantly worse under hypoxia and low glucose (*p < 0.05 versus control). Results
are normalized to the viability of cells at normoxia, in high-glucose media, without HIF-1 blockade.
B: Cell cycle analysis of 4T1 and PC-3 cells exposed to nutrient deprivation, as in A. Results are expressed as the change in size of the G1 population as
compared to normoxic, high-glucose controls. HIF-1 inhibition attenuates G1 arrest after hypoxia but enhances it after hypoxia and glucose deprivation
(*p < 0.05).
C: 4T1 tumors grown in vivo demonstrate varying spatial patterns of proliferative indices depending on HIF-1 activity. Representative fields are shown. Blue,
IV-injected perfusion marker (Hoechst 33342); red, proliferation marker (Ki-67). Scale bar, 100 m. Similar results were obtained for PC-3 tumors (data
not shown).
D: The Ki-67 index (percentage Ki-67+ area) was quantified for 4T1 tumors in 10 m bins extending from perfused vessels, out to a maximum of 605 m. n =
5/group.
E: Clonogenic assay for PC-3 cells cultured for 24 hr under hypoxia, with or without doxycycline, with or without aphidicolin (5 g/ml), and irradiated
following a brief period of reoxygenation. Cell cycle synchronization with aphidicolin caused a significant right-shift in the survival curves (open symbols; p < 0.05
versus −aph), more pronounced when combined with HIF-1 blockade (p < 0.05 versus −dox + aph).
Error bars represent the standard deviation of the mean.tumor angiogenesis. We elected against using our dominant-
negative model for this study, as we were concerned that tran-
sient HIF-1 activation, occurring before expression of the mu-
tant could be induced in vivo, could have dramatic effects on
angiogenesis. Therefore, we used our siRNA model for this
study, measuring angiogenesis in 4T1 tumors by following their
vascularity over time using dorsal skinfold window chambers.
Since HIF-1 blockade had no effect on overall 4T1 tumor
growth rate (data not shown), we could compare vascularity
between groups over time without adjusting for tumor volume.
There was a delay in initial tumor vascularization in the HIF-1-
inhibited tumor group, most pronounced at day 10 following
tumor cell inoculation (Figure 6A). After that point, however,
there were no significant differences in vascular density be-
tween the two treatment groups. Next, immunohistochemistry
was used to determine whether this parity in angiogenesis held
for larger tumors (volume, 1000 mm3; n = 5/group). Vascular
density, vessel maturity, and tumor oxygenation were all similar
for both control and knockdown tumors (see the Supplemen-
tal Data).CANCER CELL : AUGUST 2005Though it did not appear to alter baseline tumor vessel anat-
omy or physiology, our prior work suggests that HIF-1 inhibi-
tion dramatically increases tumor vessel radiosensitivity. There-
fore, we next sought to determine (1) whether our biological,
high-specificity models of HIF-1 inhibition also radiosensitized
tumor vasculature, and (2) whether the timing of HIF-1 inhibi-
tion with radiotherapy would impact this result. We used 4T1,
HCT116, and PC-3 tumors, grown in the dorsal skinfold win-
dow chamber, to monitor changes in tumor vascularity over
time following HIF-1 blockade and radiotherapy. 4T1 knock-
down tumors underwent significant vascular regression follow-
ing irradiation, whereas control tumor vessel density trended
higher (Figure 6B). Next, pre- and postradiation doxycycline
treatments were tested on HCT116 and PC-3 window chamber
tumors to determine whether these sequences would cause
differential vascular radiosensitization. Each combination in-
duced significant tumor devascularization as compared to radi-
ation alone, with neither sequence being more effective at do-
ing so than the other (Figure 6C). Therefore, HIF-1 blockade is105
A R T I C L EFigure 6. HIF-1 protects tumor vasculature
A: Serial monitoring of vascular length density in 4T1 window chamber tumors. Angiogenesis was slightly delayed in HIF-1 knockdown tumors, but tumor
vascularity was significantly different from controls only on day 10 (*p < 0.05 versus scrambled siRNA control). n = 5/group.
B: Vascular length density in 4T1 window chamber tumors following three 3 Gy fractions of radiation. Knockdown tumors underwent devascularization
beginning 48 hr after irradiation (*p < 0.05). n = 5/group.
C and D: Vascular length density in HCT116 (C) and PC-3 (D) window chamber tumors following irradiation (3 × 3 Gy). Doxycycline exposure began 1 week
prior to radiation (Dox + RT), or immediately after radiation (RT + Dox). Vascular regression occurred to similar degrees for both groups treated with radiation
and doxycycline, regardless of sequencing (*p < 0.05 versus Dox + RT and RT + Dox). Doxycycline alone did not affect vascular density (data not shown).
n = 5/group.
Error bars represent the standard deviation of the mean.an effective means of enhancing radiation damage to tumor
vasculature, irrespective of treatment sequencing.
HIF-1 blockade is maximally effective following radiation
Results from the above experiments suggest that HIF-1 influ-
ences tumor cell radiosensitivity through multiple mechanisms.
By promoting apoptosis, metabolism, and proliferation of nutri-
ent-starved cells, HIF-1 enhances tumor radiosensitivity. In
contrast, HIF-1 also dramatically decreases tumor radiosensi-
tivity through cytokine-mediated protection of tumor vascula-
ture. Importantly, the time course over which these opposing
mechanisms occur is likely distinct, raising the possibility that
the proper timing of HIF-1 blockade could optimize its effects
on radiotherapy. Specifically, the effects of HIF-1 inhibition on
apoptosis, metabolism, and proliferation would be expected to
influence the immediate response of tumors to ionizing dam-
age; therefore, these mechanisms may not significantly influ-
ence treatment outcome unless modified before radiation is
delivered. Consistent with this hypothesis, we found that post-
radiation HIF-1 blockade failed to modify tumor cell clonoge-
nicity in situations where preradiation HIF-1 inhibition had suc-
ceeded in doing so (Figure S4). The vascular effects of HIF-1106blockade, on the other hand, have been shown here to cause
radiosensitization regardless of sequencing with radiation (Fig-
ure 6); therefore, this mechanism could significantly influence
treatment outcome whether modified before or after radiother-
apy. Based on this reasoning, it was hypothesized that postra-
diation HIF-1 blockade would have significantly greater antitu-
mor effects than would preradiation HIF-1 inhibition.
To test this hypothesis, HCT116 and PC-3 tumors were ran-
domized to the treatment groups outlined in Figure 7A, and the
corresponding growth delay data are displayed in Figures 7B
and 7C. Average tumor volumes among the various treatment
groups for each tumor line were not significantly different at the
times of randomization (1 week postimplantation) or irradiation
(2 weeks postimplantation). Subsequent growth rates were not
affected by HIF-1 inhibition alone. Combining HIF-1 blockade
with radiation, however, significantly enhanced tumor growth
delay. For HCT116 tumors, the efficacy of this approach was
highly dependent on sequencing. Preradiation HIF-1 blockade
extended the time to reach 5× initial treatment volume by ap-
proximately 3 days (p < 0.05 versus radiotherapy [RT] alone).
Postradiation HIF-1 inhibition extended the same interval by 15
days (p < 0.001 versus RT alone). By this metric, the “radiationCANCER CELL : AUGUST 2005
A R T I C L EFigure 7. Sequencing determines effect of HIF-1 inhibition on radiation
A: A treatment timeline is shown for each group, indicating the times of
tumor implantation, initial doxycycline exposure (D), and irradiation (R),
along with the length of doxycycline exposure (gray arrow). Radiation was
given in three 4 Gy fractions spaced by 12 hr each. Doxycycline treatment
began in group 5 immediately following the last fraction of radiation. Tu-
mor growth delay data are shown for HCT116 (B) and PC-3 (C) tumors.
Tumor regrowth after treatment was significantly delayed for all irradiated
groups (p < 0.05 versus NT). Preradiation doxycycline treatment caused a
significantly prolonged growth delay (p < 0.05 versus RT) for both tumor
types. Postradiation doxycycline treatment caused a marked enhance-
ment in growth delay, significantly greater than that for both of the other
irradiated groups (p < 0.05). The difference in efficacy between the two
sequencing schema was much more pronounced for HCT116 tumors as
compared to PC-3 tumors. n = 8/group. Error bars represent the standard
deviation of the mean.first” strategy extended tumor growth delay for HCT116 tumors
five times further than did the alternative sequencing. For PC-3
tumors, the difference in efficacy between the two sequenc-
ing strategies was much less pronounced. Preradiation HIF-1
blockade caused significant growth delay (p < 0.05 versus RT
alone), extending the time to reach 5× initial treatment volume
by approximately 8 days. Postradiation HIF-1 inhibition also
significantly prolonged the growth delay (p < 0.05 versus RT
alone) and extended the 5× regrowth time by approximately 10
days. Therefore, the efficacy of combined radiotherapy and
HIF-1 inhibition is dependent on the sequencing of treatments,CANCER CELL : AUGUST 2005but the magnitude of the sequencing effect may vary from tu-
mor to tumor.
Discussion
The idea that HIF-1 may be a good target for cancer therapy
is not a new one (Giaccia et al., 2003; Semenza, 2003). HIF-1 is
active in virtually all tumors, and it plays key roles in promoting
malignant behavior. Moreover, some preclinical studies on xe-
nograft tumors have shown that HIF-1 inhibition slows tumor
growth (Kung et al., 2000), while its activation accelerates
growth (Ravi et al., 2000). Though these data establish the
rationale for using HIF-1 blockade as a single-modality cancer
therapy, work done previously by our group suggests that
HIF-1 blockade will work best when combined with other treat-
ments such as radiotherapy.
However, as discussed above, HIF-1 may also serve to ra-
diosensitize tumors through various mechanisms. Indeed, we
have demonstrated here that HIF-1 can enhance tumor radio-
sensitivity through increasing apoptotic potential, proliferation
rates, and ATP metabolism. Because the importance of these
effects varies with the tumor microenvironment and target cell
type, the impact of HIF-1 inhibition is also likely to differ de-
pending on location within the tumor (Table 1). HIF-1 blockade
has pronounced radiosensitizing effects on tumor vasculature,
seemingly irrespective of vessel location. The impact of HIF-1
inhibition on radiosensitivity of tumor cells, on the other hand,
probably depends strongly on the local physiological microen-
vironment. For well-oxygenated tumor cells, HIF-1 is unlikely
to be active, and its inhibition is probably not consequential.
For hypoxic cells with sufficient access to glycolytic energy
stores, HIF-1 inhibition will increase proliferation rates by abro-
gating G1 blockade mechanisms while decreasing apoptotic
potential by suppressing p53 activation—the balance of these
two effects would likely minimize the overall impact on radio-
sensitivity for these cells. For tumor cells low on oxygen and
nutrients, called “distal” cells here, HIF-1 inhibition would likely
lead to significant radioresistance.
Were these two compartments—vasculature and distal tu-
mor cells—equally affected by HIF-1 inhibition, the ultimate im-
pact on radiosensitivity would depend on which is the more
important determinant of radiation outcome. A strong case has
recently been made for the importance of tumor vasculature
in determining radiosensitivity (Garcia-Barros et al., 2003). An
equally compelling argument could be made for the impor-
tance of distal tumor cells. Bordering on necrosis, these cells
are initially protected from radiation damage by their microen-
vironment. As tumors reoxygenate and reperfuse during frac-
tionated radiotherapy, they can overcome their prior growth re-
strictions and contribute to treatment failure. Therefore, it is
conceivable that both of these compartments, with radiosensi-
tivities highly dependent on HIF-1 activity, could contribute
strongly to overall tumor radioresponsiveness.
If one hopes to optimize the combination of HIF-1-inhibiting
and cytotoxic therapies, then, the strategy used should aim to
maximize the effects of HIF-1 blockade on the vasculature
while minimizing effects on the distal tumor cells. This could be
achieved either through spatial or temporal selectivity of HIF-1
blockade. Since tumor vasculature is most influenced by cy-
tokine secretion from nearby (“proximal”) tumor cells, spatial
targeting of HIF-1 inhibition to the vasculature could be accom-107
A R T I C L ETable 1. Summary of results
Compartment Apoptosis Metabolism Proliferation Radiosensitivity
Vasculature [ + 4 + 4 = [
Proximal tumor Y + 4 + [ = 4
Distal tumor Y + Y + Y = Y
HIF-1 inhibition either increases ([), decreases (Y), or has no effect on (4) tumor and endothelial cell apoptosis, metabolism, and proliferation; the sum total of these
effects determines how it influences radiosensitivity. “Proximal tumor” refers to tumor cells near perfused vasculature that are hypoxic but supplied with nutrients;
“distal tumor” refers to tumor cells far from perfused vasculature that are both hypoxic and nutrient depleted.plished by delivering the inhibitory agent via macromolecular
carriers that penetrate only as far as these cells are located.
An alternative, somewhat simpler approach would be to target
the effects of HIF-1 blockade to tumor vasculature through
specific timing of therapeutic delivery, as was done here. The
window of opportunity for radiosensitizing tumor vessels with
HIF-1 inhibition was large, since the sequencing of treatments
was irrelevant. The therapeutic window for changing tumor cell
radiosensitivity with HIF-1 blockade is narrower, as demon-
strated above. Since HIF-1 mainly modulates processes that
influence the immediate response to ionizing radiation damage
in tumor cells, HIF-1 must be inhibited prior to irradiation to
have an effect in this compartment. Therefore, “radiation first”
sequencing maximizes the efficacy of combining HIF-1 block-
ade with cytotoxic therapy by preferentially exploiting the anti-
vascular component of this strategy.
Due to promising preclinical trials, there is much interest in
developing new targeted therapy strategies for radiosensitizing
tumor vasculature. We feel that HIF-1 should be a leading can-
didate among those proposed so far. Because it targets signal-
ing pathways that promote vascular radioresistance in tumors,
but not in normal tissues, HIF-1 blockade is a tumor-specific
approach to this problem. By targeting multiple nonoverlapping
vascular-protecting pathways at their upstream source, HIF-1
blockade is also a potent multifaceted approach to this prob-
lem. Moreover, the data presented here may underestimate the
efficacy of this approach. Our model studied the effects of HIF-1
inhibition on tumor cells only, but its effects on stromal cells
may be highly significant as well. It has recently been reported
that HIF-1 activity is important within tumor endothelial cells
themselves, wherein it serves to fuel an autocrine VEGF loop
that maintains angiogenesis and vascularity (Tang et al., 2004).
Since VEGF is a key promoter of endothelial radioresistance
(Gorski et al., 1999), HIF-1 inhibition within tumor endothelial
cells may increase overall tumor radiosensitivity beyond the
levels seen here. Such a mechanism might counterbalance the
protective effects of HIF-1 blockade for p53-expressing tu-
mors, rendering the overall effect beneficial irrespective of the
tumor cell radioprotection. This possibility certainly warrants
further investigation.
Further underscoring the importance of coupling HIF-1 inhi-
bition with radiation, our studies suggest that HIF-1 blockade
may be an ineffective single-modality therapy. Several prior
studies have reported tumor growth inhibition after HIF-1
blockade. However, many of these experiments used fibro-
blasts or stem cells derived from HIF-1α knockout mice in-
stead of established tumor lines (Carmeliet et al., 1998; Ryan
et al., 1998). HIF-1α mutant proteins have been used in the
past to successfully reduce tumor growth rates (Kung et al.,1082000), but to our knowledge, they have never before been used
solely in already-established tumors as was done here. Since
our approach seems more clinically relevant, we think it de-
serves careful consideration. In contrast, our model of consti-
tutive HIF-1 blockade also failed to show tumor growth restric-
tion. To our knowledge, no prior studies have used siRNA to
inhibit HIF-1α activity in vivo—the discrepancy here may, there-
fore, be methodological. Future work will need to be done to
clarify whether HIF-1 inhibition by itself is an effective antican-
cer tool.
This work may have important implications for the way in
which HIF-1 inhibitors are used in the clinic. Our data suggest
that HIF-1 blockade will be suboptimally effective if used prior
to cytotoxic therapy. Although this sequencing may be a suit-
able approach for other antiangiogenic agents (Winkler et al.,
2004), HIF-1 inhibitors might impede therapy if used this way.
As an alternative, we propose that HIF-1 blockade should be
used concurrently with chemotherapy and/or radiotherapy.
One way to do so would be to administer HIF-1 blockade
throughout the course of chemotherapy/radiotherapy, thereby
maximally sensitizing the tumor vasculature. Alternatively, one
could inhibit HIF-1 during breaks from treatment (e.g., over the
weekend for fractionated radiotherapy or between cycles of
chemotherapy), thereby minimizing the potential for interfering
with their cytotoxicity.
It is also important to note that patient selection may play an
eventual role in maximizing the potency of HIF-1 blockade. The
mechanisms of radiation-induced HIF-1 activation are depen-
dent on the presence of tumor hypoxia before treatment
(Moeller et al., 2004). Therefore, methods of identifying tumors
with high hypoxic fractions could be useful in selecting patients
who will benefit from HIF-1 blockade during chemo/radiother-
apy. Similarly, tumors found to have high HIF-1α expression
levels may respond best to this type of treatment. There is al-
ready a large body of work demonstrating that HIF-1α expres-
sion correlates with poor clinical outcome (Semenza, 2002). If
this at-risk population could be identified and offered HIF-1
blockade as adjunctive therapy, they might benefit greatly. It
was also shown here that p53 status is a major determinant of
how HIF-1 affects tumor radiosensitivity. As a result, it may also
be beneficial to use HIF-1 inhibition preferentially for tumors
with documented p53 mutations, as they will be less sensitive
to its radioresistance-inducing effects. Interestingly, clinical
studies have previously shown that the finding of nonfunctional
p53 and high levels of HIF-1α portends a particularly poor
prognosis (Birner et al., 2001). The combined HIF-1 blockade/
radiotherapy regimen described above may be highly effective
for this difficult-to-treat tumor population, suggesting againCANCER CELL : AUGUST 2005
A R T I C L Ethat patient selection may be critical to optimizing this thera-
peutic option. These issues warrant further study.
Experimental procedures
Cloning
For details, please see the Supplemental Data.
Irradiation
Radiation was delivered using a Mark IV cesium irradiator (dose rate = 7
Gy/min; JL Shepherd) to the specified dose. Cells were irradiated in a single
fraction. Tumors were irradiated in three fractions, spaced by 12 hr each,
to the specified doses.
Caspase assay
Samples of 103 cells, plated in 96-well plates, were analyzed for caspase
activity 6 hr after irradiation using the Caspase-Glo 3/7 kit (Promega).
DNA content analysis
Cells were harvested 48 hr after treatment, fixed in ice-cold 70% ethanol,
and stained with propidium iodide (Sigma) in the presence of RNase (Qia-
gen). Flow cytometry was then used to determine the relative sizes of the
apoptotic, G1, S, and G2/M cell populations.
Protein analysis
For details, please see the Supplemental Data.
Clonogenic assay
Cells were pretreated as indicated, harvested, exposed to the specified
doses of radiation, and then sparsely plated. Seven days later, cells were
fixed in methanol:acetone and stained with crystal violet to facilitate count-
ing of colonies (R50 cells). Clonogenic survival was calculated for each
radiation dose after correcting for plating efficiency.
Glucose consumption
After 24 hr of the indicated treatment, samples of tissue culture media were
analyzed using microdialysis (CMA/Microdialysis). The difference in glucose
content in the media between 0 and 24 hr, normalized to protein content in
the media, was calculated as the glucose consumption rate.
In vitro ATP assay
After 24 hr of treatment, samples of 103 cells in 96-well plates were assayed
for total cellular ATP levels using the CellTiter-Glo Luminescent Cell Viability
Kit (Promega).
Immunohistochemistry
For details, please see the Supplemental Data.
Ex vivo bioluminescence ATP assay
For details, please see the Supplemental Data.
Window chamber studies
Window chambers were implanted and imaged as previously described
(Moeller et al., 2004). Tumors were implanted by injecting 104 4T1 cells or
105 HCT116 cells into the dorsal skinfold at the time of surgery. Treatments
were not initiated for window chamber tumors until they had a vascular
network allowing visible blood flow across the entire tumor. ImageJ was
used to trace and measure the length of the vasculature in window chamber
tumors. Total vascular length was then divided by the two-dimensional tu-
mor area, determined using ImageJ, to calculate the vascular length density.
Growth delay studies
HCT116 cells (106) were injected into the flank of athymic nude mice. Tumor
volumes were calculated every 3–4 days, based on caliper measurements
of the short (a) and long (b) tumor diameters (volume = a2b/2). Animals were
randomized to treatment groups once the average tumor volume surpassed
50 mm3. Animals in each group were sacrificed once the average tumor
volume for that group reached 1000 mm3.CANCER CELL : AUGUST 2005Supplemental data
The Supplemental Data include Supplemental Results, Experimental Pro-
cedures, and four figures and can be found with this article online at http://
www.cancercell.org/cgi/content/full/8/2/99/DC1/.
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